Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Admission of a major data error in previous roxadustat presentations leaves the novel anaemia pill’s future in doubt.
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.